|View printer-friendly version|
|March 26, 2003 4:34 p.m.|
|Teva & Lundbeck Announce Successful Completion of Rasagiline Phase III Clinical Program in Parkinson's Disease|
U.S. and European submissions expected in the second half of 2003
Jerusalem, Israel, March 26, 2003 - Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) and H. Lundbeck A/S(CSE: LUN.CO) are pleased to announce the successful completion of two phase III clinical trials of rasagiline in patients with advanced Parkinson's disease. In both trials, statistically significant results for the primary endpoint were achieved. Each of the studies, which compared once-daily dosages of rasagiline to placebo as an adjunct treatment to levodopa, demonstrated significant reductions in the duration of the "Off" time (a state in which patients are unable to function normally). The results of these two trials follow the successful results of an earlier phase III trial which demonstrated the efficacy of rasagiline as monotherapy in early-stage Parkinson's disease.